Pain of endometriosis: effects of nafarelin and danazol therapy.
OBJECTIVE
To compare the efficacy of nafarelin acetate with danazol in the treatment of dysmenorrhea, dyspareunia, and pelvic pain associated with endometriosis.


METHODS
Prospective, randomized double-blind controlled study. PATIENTS, SETTING, TREATMENTS: Two hundred thirteen patients aged 18 to 48 with laparoscopically confirmed pelvic endometriosis and dysmenorrhea, dyspareunia or pelvic pain were randomly assigned to 6 months of treatment with either nafarelin acetate 800 micrograms per day or 400 micrograms per day, or danazol 800 micrograms per day.


METHODS
The percentage of patients with dysmenorrhea, dyspareunia or pelvic pain before treatment who still had these symptoms after 6 months of treatment and 6 months following completion of treatment. RESULTS [table: see text]


CONCLUSIONS
Nafarelin acetate and danazol both provided significant relief of dysmenorrhea, dyspareunia, and pelvic pain during treatment and for 6 months following treatment in women with endometriosis.
Department of Statistics, Syntex Research, Palo Alto, California.
G D
GD
Adamson
L
L
Kwei
R A
RA
Edgren
D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004412:Dysmenorrhea / Q000188:drug therapy* / Q000209:etiology; D004414:Dyspareunia / Q000188:drug therapy* / Q000209:etiology; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017274:Nafarelin / Q000008:administration & dosage / Q000627:therapeutic use*; D010147:Pain Measurement; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology; D011446:Prospective Studies
D017274:Nafarelin; D003613:Danazol